| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/24/2023 | 142.23% | Capital One | → $7 | Downgrades | Overweight → Equal-Weight |
| 04/04/2023 | 246.04% | JP Morgan | $12 → $10 | Maintains | Neutral |
| 11/14/2022 | 211.44% | Morgan Stanley | $12 → $9 | Maintains | Equal-Weight |
| 11/10/2022 | 176.84% | Goldman Sachs | $9 → $8 | Maintains | Neutral |
| 08/15/2022 | 315.25% | Morgan Stanley | $10 → $12 | Maintains | Equal-Weight |
| 08/10/2022 | 522.88% | Chardan Capital | $19 → $18 | Maintains | Buy |
| 08/09/2022 | 419.07% | Truist Securities | $10 → $15 | Maintains | Buy |
| 08/09/2022 | 211.44% | Goldman Sachs | $5 → $9 | Maintains | Neutral |
| 08/02/2022 | 107.63% | Citigroup | → $6 | Downgrades | Neutral → Sell |
| 05/24/2022 | 73.02% | Goldman Sachs | $7 → $5 | Maintains | Neutral |
| 05/17/2022 | 246.04% | Morgan Stanley | $12 → $10 | Maintains | Equal-Weight |
| 05/11/2022 | 142.23% | Goldman Sachs | $8 → $7 | Maintains | Neutral |
| 04/12/2022 | 315.25% | Morgan Stanley | $17 → $12 | Maintains | Equal-Weight |
| 02/24/2022 | 488.28% | Morgan Stanley | $77 → $17 | Maintains | Equal-Weight |
| 02/24/2022 | 315.25% | Citigroup | $70 → $12 | Maintains | Neutral |
| 02/24/2022 | 626.69% | JP Morgan | $90 → $21 | Downgrades | Overweight → Neutral |
| 02/07/2022 | 1630.22% | Barclays | $81 → $50 | Maintains | Underweight |
| 02/02/2022 | 3014.4% | JP Morgan | → $90 | Upgrades | Neutral → Overweight |
| 02/01/2022 | 2564.54% | Morgan Stanley | $122 → $77 | Maintains | Equal-Weight |
| 01/26/2022 | 2322.31% | Citigroup | $114 → $70 | Maintains | Neutral |
| 01/18/2022 | 4121.75% | Morgan Stanley | $119 → $122 | Maintains | Equal-Weight |
| 11/11/2021 | 3844.91% | Citigroup | $103 → $114 | Maintains | Neutral |
| 05/11/2021 | 2875.98% | Barclays | $90 → $86 | Maintains | Underweight |
| 05/11/2021 | 3498.86% | BMO Capital | $138 → $104 | Maintains | Market Perform |
| 05/11/2021 | 5056.07% | Roth Capital | $155 → $149 | Upgrades | Neutral → Buy |
| 05/04/2021 | 4986.86% | Truist Securities | $89 → $147 | Maintains | Buy |
| 04/19/2021 | 4017.93% | Morgan Stanley | $133 → $119 | Maintains | Equal-Weight |
| 03/12/2021 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 03/08/2021 | 4502.39% | Morgan Stanley | $125 → $133 | Maintains | Equal-Weight |
| 03/01/2021 | 3014.4% | Barclays | $52 → $90 | Downgrades | Equal-Weight → Underweight |
| 02/17/2021 | 5263.69% | Roth Capital | $133 → $155 | Downgrades | Buy → Neutral |
| 01/25/2021 | 5021.46% | BMO Capital | $145 → $148 | Downgrades | Outperform → Market Perform |
| 12/17/2020 | 5298.3% | Berenberg | → $156 | Initiates Coverage On | → Buy |
| 12/11/2020 | 4537% | Citigroup | → $134 | Initiates Coverage On | → Neutral |
| 11/30/2020 | 4225.56% | JP Morgan | → $125 | Downgrades | Overweight → Neutral |
| 11/16/2020 | 4225.56% | Morgan Stanley | → $125 | Downgrades | Overweight → Equal-Weight |
| 11/13/2020 | 3533.47% | Goldman Sachs | → $105 | Downgrades | Buy → Neutral |
| 11/10/2020 | 4502.39% | Roth Capital | $124 → $133 | Maintains | Buy |
| 07/28/2020 | 2979.8% | SunTrust Robinson Humphrey | $90 → $89 | Maintains | Buy |
| 05/14/2020 | 3014.4% | SunTrust Robinson Humphrey | $101 → $90 | Maintains | Buy |
| 04/15/2020 | 2668.36% | Morgan Stanley | $82 → $80 | Maintains | Overweight |
| 03/31/2020 | 2460.73% | BMO Capital | → $74 | Initiates Coverage On | → Outperform |
| 03/03/2020 | 2668.36% | Goldman Sachs | → $80 | Initiates Coverage On | → Buy |
| 02/18/2020 | 2287.71% | Barclays | → $69 | Downgrades | Overweight → Equal-Weight |
| 02/06/2020 | 3395.05% | SunTrust Robinson Humphrey | → $101 | Initiates Coverage On | → Buy |
| 01/03/2020 | 3360.45% | HC Wainwright & Co. | → $100 | Initiates Coverage On | → Buy |
| 12/24/2019 | 2737.57% | JP Morgan | → $82 | Initiates Coverage On | → Overweight |
| 12/17/2019 | 2737.57% | Morgan Stanley | $33 → $82 | Maintains | Overweight |
| 02/20/2019 | 678.6% | Chardan Capital | → $22.5 | Initiates Coverage On | → Buy |
| 10/29/2018 | 592.09% | Barclays | → $20 | Initiates Coverage On | → Overweight |
| 10/29/2018 | 384.46% | B of A Securities | → $14 | Initiates Coverage On | → Buy |
| 10/29/2018 | 592.09% | Morgan Stanley | → $20 | Initiates Coverage On | → Overweight |
What is the target price for Kodiak Sciences (KOD)?
The latest price target for Kodiak Sciences (NASDAQ: KOD) was reported by Capital One on July 24, 2023. The analyst firm set a price target for $7.00 expecting KOD to rise to within 12 months (a possible 142.23% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Kodiak Sciences (KOD)?
The latest analyst rating for Kodiak Sciences (NASDAQ: KOD) was provided by Capital One, and Kodiak Sciences downgraded their equal-weight rating.
When is the next analyst rating going to be posted or updated for Kodiak Sciences (KOD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kodiak Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kodiak Sciences was filed on July 24, 2023 so you should expect the next rating to be made available sometime around July 24, 2024.
Is the Analyst Rating Kodiak Sciences (KOD) correct?
While ratings are subjective and will change, the latest Kodiak Sciences (KOD) rating was a downgraded with a price target of $0.00 to $7.00. The current price Kodiak Sciences (KOD) is trading at is $2.89, which is within the analyst's predicted range.